Intermal Application No PCT/JP2005/001172

IPC 7	C12Q1/48 G01N33/574			
According to	o International Patent Classification (IPC) or to both national classification	ation and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 7	cumentation searched (classification system followed by classification C12Q G01N	on symbols)		
Documental	ion searched other than minimum documentation to the extent that s	such documents are included in the fields se	earched	
		·		
	ata base consulted during the international search (name of data batherna? LIPT Data PAI EMPACE PTOCI			
FLO-TH	ternal, WPI Data, PAJ, EMBASE, BIOSI			
	•			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.	
χ	WO 02/090578 A (CAMBRIDGE UNIVERS	SITY	1-16	
	TECHNICAL SERVICES LIMITED; CHRON THERAPEUTICS L)		•	
	14 November 2002 (2002-11-14)			
	the whole document	,		
	pages 34,51,52 claims 2,3		•	
Α.	REA STEPHEN ET AL: "Regulation o	æ	1_16	
Λ	chromatin structure by site-speci	1	1-16	
•	histone H3 methyltransferases"	ONDON		
1	NATURE, MACMILLAN JOURNALS LTD. L GB,			
	vol. 406, no. 6796, August 2000 ((2000-08),		
	pages 593-599, XP002154907 ISSN: 0028-0836			
	the whole document			
	page 595, column 2, paragraph 1	,	·	
	<u>-</u>	-/		
	ner documents are listed in the continuation of box C.	χ Patent family members are listed in	аплех.	
		"T" later document published after the linter or priority date and not in conflict with	the application but	
consid	ent defining the general state of the last which is not ered to be of particular relevance focument but published on or after the international	cited to understand the principle or the invention	eory underlying the	
 E earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or 		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
which	is cited to establish the publication date of another or other special reason (as specified)	"Y" document of particular relevance; the cl cannot be considered to involve an inv	almed invention	
O' docume	ent referring to an oral disclosure, use, exhibition or neans	document is combined with one or mo ments, such combination being obviou	re other such docu-	
	ent published prior to the international filing date but an the priority date claimed	in the art. *&' document member of the same patent f	amily	
Date of the	actual completion of the international search	Date of mailing of the international search report		
1!	5 July 2005	29/07/2005		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2		Authorized officer		
	NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Jenkins, G		

Intermenal Application No
PCT/JP2005/001172

.(Continua	tion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
P , X	HAMAMOTO RYUJI ET AL: "SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells" NATURE CELL BIOLOGY, vol. 6, no. 8, August 2004 (2004-08), pages 731-740, XP002336164 ISSN: 1465-7392 the whole document WO 03/027143 A (JAPAN AS REPRESENTED BY THE PRESIDENT OF THE UNIVERSITY OF TOKYO; ONCO) 3 April 2003 (2003-04-03)		1-16
	the whole document		
		•	·
			·
	,		
		:	
·			
•			
		•	•
			·
		•	
	·		
	•		
	."	•	
		•	

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

PCT/JP2005/001172

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 17-20 because they relate to subject matter not required to be searched by this Authority, namely:
Claims 18-20: Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
Claims Nos.: 17-20 Claims Nos.: 17-20 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
I fils international Searching Admonty reason maniple weeks as well as the search of t
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
The additional search fees were accompanied by the applicant's protest.
hemark on trotage
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Claims Nos.: 17-20

Claims 18-20: Rule 39.1(iv) PCT - Method for treatment of the human or

animal body by therapy

Continuation of Box II.2

Claims Nos.: 17-20

The subject-matter of claims 17-20 is rendered vague and unclear as it tries to define agents in terms of a result to be achieved, i.e. that they decrease ZNFN3A1-mediated methylation or interactions between ZNFN3A1 and HSP9OA or S-adenosyl-L-methionine (Article 6 PCT). Furthermore, none of the compounds alluded to in said claims are disclosed in the description. Thus, the subject-matter of said claims is unsupported in the sense of Article 6 PCT and not disclosed in the application in the sense of Article 5 PCT. The lack of clarity, support and disclosure is in this case so grave that no meaningful search can be performed for these claims.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

formation on patent family members

Intermonal Application No
PCT/JP2005/001172

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
WO 02090578	Α	WO 02090578 A2 14-	19-05-2004 14-11-2002 02-12-2004			
WO 03027143	A	03-04-2003	CN EP EP WO WO JP JP	1592793 / 1434879 / 1430152 / 03027322 / 03027143 / 2005511023 2005503176	A2 A2 A2 A2 T	09-03-2005 07-07-2004 23-06-2004 03-04-2003 03-04-2003 28-04-2005 03-02-2005 27-01-2005
			US CA	2004235018 / 2399569 /	A1	25-11-2004 25-03-2003